Substituted fused tricyclic compounds, compositions and medicinal applications thereof

US9115133B2 · kind B2 · utility

Assignee

• Advinus Therapeutics Limited

Inventors

• Dinesh Barawkar · Lake Forest, US
• Tanushree Bende · Pune, IN
• Robert Zahler · Pennington, US
• Anish Bandyopadhyay · Pune, IN
• Robindro Sarangthem · Pune, IN
• Jignesh Doshi · Pune, IN
• Yogesh Waman · Pune, IN
• Rushikesh Jadhav · Pune, IN
• Umesh Singh · Pune, IN

Key dates

• Filing date: Mar 21, 2012
• Grant date: Aug 25, 2015
• Expiry date: Mar 21, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcera…